Li Kang Biomedical Co., Ltd. (TPEX:6242)
34.00
0.00 (0.00%)
Aug 19, 2026, 9:59 AM CST
Li Kang Biomedical Revenue
Li Kang Biomedical had revenue of 161.99M TWD in the quarter ending June 30, 2026, a decrease of -1.59%. This brings the company's revenue in the last twelve months to 573.36M, down -2.92% year-over-year. In the year 2025, Li Kang Biomedical had annual revenue of 589.21M with 4.19% growth.
Revenue (ttm)
573.36M
Revenue Growth
-2.92%
P/S Ratio
1.89
Revenue / Employee
4.70M
Employees
122
Market Cap
1.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 589.21M | 23.69M | 4.19% |
| Dec 31, 2024 | 565.52M | -63.86M | -10.15% |
| Dec 31, 2023 | 629.38M | -54.87M | -8.02% |
| Dec 31, 2022 | 684.25M | 297.28M | 76.82% |
| Dec 31, 2021 | 386.97M | -69.75M | -15.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hotai Motor | 300.97B |
| Far Eastern New Century | 260.82B |
| Taiwan Mobile | 202.34B |
| King Slide Works | 25.60B |
| Redwood Group | 2.76B |
| KINGZA International CO.,Ltd. | 2.02B |
| New Palace International | 1.61B |
| Dacome International | 717.01M |